Pharmabiz

Flow Neuroscience launches FL-100 in US; first US FDA-approved at-home tDCS treatment for depression

Flow Neuroscience launches FL-100 in US; first US FDA-approved at-home tDCS treatment for depression: Malmö, Sweden Saturday, September 19, 2026, 16:00 Hrs [IST] Flow Neuroscienc ...
Pharmabiz

1ST Biotherapeutics, SK Biopharmaceuticals to advance 1ST-104, a novel drug candidate for the treatment of Parkinson's disease

ST Biotherapeutics, SK Biopharmaceuticals to advance 1ST-104, a novel drug candidate for the treatment of Parkinson's disease: Yongin, South Korea Saturday, September 19, 2026, 1 ...
Pharmabiz

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment: United Kingdom Saturday, September 19, 2026, 15:0 ...
Pharmabiz

Longeveron ELPIS II phase 2b trial of laromestrocel to treat hypoplastic left heart syndrome fails to meet the primary efficacy endpoint

Longeveron ELPIS II phase 2b trial of laromestrocel to treat hypoplastic left heart syndrome fails to meet the primary efficacy endpoint: Miami Saturday, September 19, 2026, 17:30 ...
Pharmabiz

Xenon announces azetukalner NDA submission to US FDA for focal seizures, provides update on psychiatry clinical program

Xenon announces azetukalner NDA submission to US FDA for focal seizures, provides update on psychiatry clinical program: Vancouver, British Columbia Saturday, September 19, 2026, ...
Pharmabiz

Aesthetics Medispa introduces Celluma LED therapy for acne, skin recovery and pain management

Aesthetics Medispa introduces Celluma LED therapy for acne, skin recovery and pain management: Our Bureau, Mumbai Saturday, September 19, 2026, 14:45 Hrs [IST] Aesthetics Medispa, ...
Pharmabiz

Quotient Sciences proprietary AI-enhanced solution optimizes formulation in clinical study

Quotient Sciences proprietary AI-enhanced solution optimizes formulation in clinical study: Nottingham, England Saturday, September 19, 2026, 18:00 Hrs [IST] Quotient Sciences, a ...
Pharmabiz

US FDA accepts and grants priority review status to Alexion’s BLA for efzimfotase alfa to treat patients with hypophosphatasia aged 2 years and older

US FDA accepts and grants priority review status to Alexion’s BLA for efzimfotase alfa to treat patients with hypophosphatasia aged 2 years and older: Cambridge, UK Saturday, Se ...
Pharmabiz

Kardi Ai to launch AI-powered ECG monitoring technology in India

A new generation of AI-powered long-term cardiac monitoring technology is set to enter the Indian market, with the official launch of Kardi Ai scheduled for September 26 in Hyderabad, disclosed Dr.
Pharmabiz

EMA committee recommends approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

EMA committee recommends approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis: Basel Saturday, September 19, 2026, 14:00 Hrs [IST] Roche an ...
Pharmabiz

JP Nadda reviews health sector progress in MP; focusing on healthcare infrastructure, medical education

JP Nadda reviews health sector progress in MP; focusing on healthcare infrastructure, medical education: Our Bureau, Mumbai Saturday, September 19, 2026, 13:40 Hrs [IST] Union min ...
Pharmabiz

QMS Medical Allied Services completes 100% acquisition of Saarathi Healthcare

QMS Medical Allied Services Ltd (QMS MAS) has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary of the company. The move marks an important step in QMS ...